Some of what I've been learning
This is the part I've spent the most time on — what actually works, what the industry gets wrong, and where I think we'd fit. I'd rather show you my thinking than summarize it. Tell me where I'm off.
← Back to the brief · The market research → · The science room →
01 · How the product actually works
The outer layer of skin is dead cells (bricks) held together by fats — ceramides, cholesterol, fatty acids (mortar). When the mortar thins out, water escapes and irritants get in. That's dryness, tightness, redness, sensitivity. "Barrier care" means replacing the mortar.
Two things surprised me. The ratio of those three fats has to be roughly right — wrong ratios can actually slow repair, so "contains ceramides" on a label means very little. And the product has to be slightly acidic, around pH 4.5–5.0, because the enzymes that rebuild the mortar only work in acid. Most brands don't publish their pH. I'd like us to.
Thousands of ingredients out there, maybe a dozen with credible clinical evidence. The ones that matter to us: niacinamide (vitamin B3 — builds barrier fats and fades dark spots, very low irritation), azelaic acid (matched prescription-strength hydroquinone in a 329-person trial, gentle on deeper skin tones), vitamin C (real, but has to be quite acidic to work — which means it stings), and retinoids (effective, but over half of patients in one study got dermatitis).
The rest — most botanical extracts, most "brightening complexes" — work in a dish, unproven on a face. That's the industry's normal. I think it's also our opening.
In deeper skin tones, an irritating product causes the exact problem it's sold to fix. Sting, redness, or a too-strong acid triggers post-inflammatory hyperpigmentation — dark spots. So a woman buys a $70 brightening serum for her dark spots, it stings, and it gives her more dark spots.
That's not a small complaint. Acne-related dark spots affect about 65% of African American women versus 25% of Caucasian women. For Black dermatology patients, uneven tone is a top-two reason for the visit — for white patients it isn't in the top ten. And 41% of women with deeper skin tones say they can't find products that suit them.
02 · Where I think the category gets it wrong
"Darker skin has fewer ceramides and a weaker barrier." A lot of competitor positioning rests on this. It traces to a single one-page conference abstract from 1993; when researchers tried to replicate it in 2010, they found no difference in total ceramides. Darker skin actually measures as more resilient — more cohesive, lower pH, faster recovery.
"Nordic skin is a different skin type." There's no such thing in the literature — which stung a little, since it's our whole aesthetic. What is real is climate: cold, dry, heated indoor air measurably strips skin lipids in winter. Same ancestry, different city, different skin. So I think we sell the climate, never the ancestry.
"Our berry extract brightens skin." Cloudberry has no published clinical trial on human skin. It's a beautiful story and a real antioxidant, but if we claim efficacy from it we're doing what everyone else does. I'd rather berries be our identity and let niacinamide and azelaic acid be our proof.
I'm telling you the weak spots because you'd find them anyway, and because a brand that markets past its own evidence is a lawsuit and a bad review waiting to happen. Our whole premium depends on being the one that doesn't.
03 · Where I think that leaves us
Two levers, two very different levels of evidence — so I'd use one and refuse the other.
Winter strips barrier lipids; summer doesn't. A cold-months routine (richer cream, gentler actives) and a warm-months routine (lighter layer, more brightening) is defensible science, and it doubles our reasons to talk to a customer each year.
It's also bigger, not smaller: it speaks to everyone in Chicago in February, whatever their background.
I don't want to formulate or market "for" an ethnicity — the biology doesn't support it and the marketing ages badly.
Instead, one line that performs across the full range of skin tones, and we prove it: a clinical panel with at least 40% deeper skin tones, measured by instrument rather than someone eyeballing redness, published by skin type.
Why that last part might be a real advantage: only about 5% of dermatology trials even report participants' skin type. Testing across the full range and publishing it is cheap for us and awkward for competitors to copy — they'd have to admit they never did it.
So the sentence I'd want us to own isn't "Nordic skincare." It's: actives that work without the sting that causes dark spots.
04 · Still open
Five things I haven't settled. This is where your head would help most.
I don't have finished answers to any of them. That's the honest reason I stopped here and called you.
← Back to the brief · The market research → · The science room →
Plain english
None of this is knowledge you should be expected to have. Here it is in one place.
The outermost layer of skin — dead cells held together by fats. It keeps water in and irritants out. Almost everything we would sell is about maintaining it.
The main fats in that barrier. Roughly half the mortar between the bricks. Most barrier creams claim to contain them; far fewer get the ratio right.
The ingredients that actually change the skin, as opposed to the ones that make a product feel or smell nice. Only about a dozen have real clinical evidence.
Vitamin B3. Our likely workhorse — it rebuilds barrier fats and fades dark spots, with very little irritation.
A gentle acid that matched prescription-strength skin lightener in a large trial, and is well tolerated on deeper skin tones.
Dark spots left behind after irritation, a breakout or a rash. Far more common and longer-lasting in deeper skin tones. The problem we would set out to solve.
How acidic something is, 0 to 14. Skin sits around 5. The enzymes that rebuild the barrier only work in that acid range, so our formulas need to as well.
Transepidermal water loss — how fast water evaporates through skin. The standard laboratory measure of whether a barrier is working.
A I–VI classification of skin by how it responds to sun. Types IV–VI are the deeper tones that clinical trials routinely under-enrol.
In a dish versus on a person. Most botanical ingredient claims are in vitro only — which is why they mean much less than they sound like.